In summary, the DNA-replication coupled SPRTN-CHK1 cross-activation loop proposed here opens a new avenue in our attempt to better understand genome instability associated with DNA replication and places the protease SPRTN as a new potential therapeutic target in cancer therapy based on targeting DDR checkpoints62. The gene discussed is SPRTN; the disease is cancer.